https://www.fresenius.com en-us Thu, 10 Apr 2025 01:00:00 +0200 Thu, 10 Apr 2025 01:00:00 +0200 Thu, 10 Apr 2025 01:00:00 +0200 <![CDATA[Fresenius makes progress on streamlining its production network]]> Tue, 01 Apr 2025 17:00:00 +0200 <![CDATA[Fresenius completes divestment of Vamed’s international project business]]> Wed, 26 Mar 2025 23:00:00 +0100 <![CDATA[Fresenius Receives FDA approval for their Denosumab Biosimilars and Secures Global Settlement ]]> here. Please click to see full Prescribing Information for Conexxence®. Please click to see full Prescribing Information for Bomyntra®. ]]> Wed, 26 Mar 2025 21:00:00 +0100 <![CDATA[Fresenius publishes 2024 Annual Report: #FutureFresenius makes the company more innovative, more focused and more efficient]]> European Sustainability Reporting Standards (ESRS). This replaces the Non-financial Report of previous Annual Reports and expands and supplements reporting topics and details. In addition, the ESRS report, like the financial report, is audited externally. The 2024 Annual Report is available in German and English as a PDF file and as an online version. Further publication and event dates for 2025: · 04/24/2025: Publication of Sustainability Highlights Magazine · 05/07/2025: Publication of the financial results for Q1 2025 · 05/23/2025: Annual General Meeting · 08/06/2025: Publication of the financial results for Q2 2025 · 11/05/2025: Publication of the financial results for Q3 2025 ]]> Mon, 17 Mar 2025 17:00:43 +0100 <![CDATA[Fresenius expands corporate headquarters in Bad Homburg with new innovation center]]> Tue, 04 Mar 2025 15:00:00 +0100 <![CDATA[Fresenius completes sale of shares in Fresenius Medical Care AG ]]> Tue, 04 Mar 2025 00:45:59 +0100 <![CDATA[Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG to 25% plus one share ]]> Mon, 03 Mar 2025 21:00:00 +0100 <![CDATA[Continuing Biopharma Growth with U.S. and EU Launch of Ustekinumab Biosimilar ]]> Wed, 26 Feb 2025 13:45:00 +0100 <![CDATA[Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase]]> Mon, 03 Feb 2025 15:00:00 +0100 <![CDATA[Fresenius reaches agreement to exit Vamed’s international project business ahead of schedule]]> Tue, 28 Jan 2025 22:00:00 +0100 <![CDATA[Fresenius Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency]]> Thu, 23 Jan 2025 16:08:30 +0100 <![CDATA[Fresenius signs agreement with Microsoft to boost companywide collaboration and IT security]]> Fri, 20 Dec 2024 18:00:00 +0100 <![CDATA[Fresenius to Expand Biopharma Portfolio with a New Licensing Agreement to commercialize a proposed Aflibercept biosimilar]]> Thu, 19 Dec 2024 23:00:00 +0100 <![CDATA[Fresenius integrates VAMED's hospital services business]]> Tue, 17 Dec 2024 21:30:00 +0100 <![CDATA[Fresenius Launches First 1mg/1 mL Generic Version of Epinephrine in the U.S.Fresenius Launches First 1mg/1 mL Generic Version of Epinephrine in the U.S.]]> Tue, 10 Dec 2024 21:30:00 +0100 <![CDATA[Fresenius and Ori Biotech Announce Collaboration to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies]]> Tue, 12 Nov 2024 16:00:00 +0100 <![CDATA[mAbxience and Egis announce strategic commercialization agreement for biosimilar candidates in Central and Eastern Europe]]> Mon, 11 Nov 2024 17:10:20 +0100 <![CDATA[Fresenius opens Helios HSK Wiesbaden, one of the most modern hospitals in Germany]]> Wed, 06 Nov 2024 14:00:00 +0100 <![CDATA[Fresenius Q3/24: Simplification and focus drives sustained performance – Outlook upgraded]]> Wed, 16 Oct 2024 16:00:00 +0200 <![CDATA[Fresenius and Cellular Origins announce development agreement for Cell and Gene Therapy Manufacturing]]>